Lymphoma, B-Cell, Marginal Zone: all 428 studies
Page 4 of 5. Open to participants first (108), then studies with results posted, then the rest; newest registration first within each.
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruitingNCT02952508Phase 2
- Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone LymphomaCompletedNCT02945319
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
- Marginal Zone Lymphoma Cohort in KoreaStatus unknownNCT02732236
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)WithdrawnNCT02576275Phase 3
- Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
- Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
- Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaTerminatedNCT02258555Phase 1
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingNCT02153580Phase 1
- Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
- Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT02049541Phase 1
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
- Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT01955499Phase 1
- Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaActive, not recruitingNCT01815749Phase 1
- Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT LymphomaActive, not recruitingNCT01808599Phase 2
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
- MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
- Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLTerminatedNCT01728207Phase 1
- Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative DiseaseCompletedNCT01720758
- Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's LymphomaCompletedNCT01701232Phase 3
- 131I-rituximab for Relapsed or Refractory Marginal Zone B-cell LymphomaStatus unknownNCT01678404Phase 2
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Endomicroscopy and Gastric MALT-lymphomaCompletedNCT01583699Not applicable
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
- Intralesional Rituximab for the Treatment of Conjunctival Indolent LymphomaCompletedNCT01514344Phase 2
- A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)TerminatedNCT01500538Phase 2
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaActive, not recruitingNCT01479842Phase 1
- Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell LymphomaWithdrawnNCT01460602Phase 1/2
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersCompletedNCT01460134Phase 1
- R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)CompletedNCT01427114Phase 2
- Lymphoma in the OrbitStatus unknownNCT01302912
- Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter PyloriCompletedNCT01264822
- Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell LymphomasWithdrawnNCT01263418Phase 2
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT01239875Early Phase 1
- Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT01238146Phase 1/2
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)CompletedNCT01213095Phase 2
- Vaccine Therapy in Treating Patients With Lymphoplasmacytic LymphomaCompletedNCT01209871Phase 1
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)CompletedNCT01164267Phase 2
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
- RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
- Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
- Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)CompletedNCT01068392Phase 2
- Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1
- Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) LymphomaCompletedNCT01015248Phase 2
- Bendamustine Plus Rituximab Versus CHOP Plus RituximabCompletedNCT00991211Phase 3
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)Status unknownNCT00927797Phase 2
- Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) TypeStatus unknownNCT00923663Phase 2
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT00891072Phase 1
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasActive, not recruitingNCT00877214Phase 3
- First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.CompletedNCT00801281Phase 3
- Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
- FAU in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00769288Phase 1
- Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaCompletedNCT00720135Phase 1
- Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) LymphomaCompletedNCT00656812Phase 2
- Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaCompletedNCT00621452Phase 1
- Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
- Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström MacroglobulinemiaCompletedNCT00566332Phase 3
- Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver DysfunctionCompletedNCT00499811Phase 1
- Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
- Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic AstrocytomaCompletedNCT00458731Phase 1
- Involved Field Radiotherapy for Non-gastric Marginal Zone LymphomaStatus unknownNCT00377195Phase 2
- Velcade in MALT Lymphoma PatientsCompletedNCT00373906Phase 2
- Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma PatientsCompletedNCT00373646Phase 2
- PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
- PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasCompletedNCT00348985Phase 1
- A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
- Gemcitabine for Marginal Zone LymphomaTerminatedNCT00337259Phase 2
- Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment OutcomeCompletedNCT00327132Not applicable
- Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other DiseasesCompletedNCT00317785Phase 2
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00293345Phase 1
- Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
- VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic TherapyTerminatedNCT00210392Phase 2
- VELCADE in MALT Lymphoma Pretreated With Prior Systemic TherapyCompletedNCT00210327Phase 2
- Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALTomaCompletedNCT00201422Not applicable
- Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
- Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00110071Phase 1
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
- SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's LymphomaTerminatedNCT00101244Phase 1
- MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or LymphomasCompletedNCT00098891Phase 1
- Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasCompletedNCT00089271Phase 1
- Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
- Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2